ERBB2 and neuroendocrine neoplasm: Pioneered by [177Lu]Lu-DOTA-TATE [9] (Lutathera®) and fueled by its regulatory approval for the treatment of neuroendocrine tumors by the FDA in early 2018 [10], intensive preclinical and clinical research toward novel targeted radiotherapeutics for oncologic targets, such as prostate-specific membrane antigen (PSMA) [11,12], human epidermal growth factor receptor 2 (HER2) [13,14], gastrin-releasing peptide receptor (GRPR) [15,16] and cholecystokinin-2-receptor (CCK2R) [17,18], among others, has been undertaken.